EyeGate’s EGP-437 for Post-Cataract Pain, Inflammation Produces Mixed Results in Phase IIb Trial

February 9, 2018: By Jon Swedien

EyeGate Pharmaceuticals’ EGP-437 outperformed the vehicle in its Phase IIb study, but the product candidate for post-cataract pain and inflammation failed to meet the study’s co-primary endpoints.

The vehicle group’s response was better than anticipated, EyeGate said.

The double-masked, randomized, vehicle-controlled Phase IIb study enrolled 106 subjects at seven US clinical sites and evaluated the safety and efficacy of transscleral iontophoretically delivered EGP-437, dexamethasone, through the company’s EyeGate II Delivery System.

Patients in the study had undergone cataract surgery and been implanted with a monofocal posterior chamber IOL. They received treatment beginning immediately after surgery.

The study’s primary endpoints were:

–Proportion of subjects with an anterior chamber cell count of zero at day seven;

–Proportion of subjects with a pain score of zero at day one.

EGP-437 demonstrated a higher rate of success compared with vehicle at all time points, but the difference between its scores and the placebo’s scores did not demonstrate statistical significance, EyeGate said.

EyeGate will continue evaluating EGP-437 for post-ocular surgery pain and inflammation, said Barbara Wirostko, MD, the company’s chief medical officer.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US FDA Grants De Novo Request for IDx-DR’s AI Diagnostic System for Diabetic Retinopathy

Allergan Launches TrueTear Intranasal Neurostimulation Device for Dry Eye

Novartis Acquires AveXis, Gene Therapy Platform for $8.7 Billion

Samsung, Biogen Reach Deal with AbbVie over Humira Biosimilar

EyePoint Secures Two US Patents for DEXYCU

SightLife Surgical Rebrands as CorneaGen, Offers New Products

Omidria Earns Listing on VA Formulary, Regains CMS Pass-Through Status

Rayner Launching 600C Monofocal Aspheric IOL in US

LENSAR Laser System Receives 510(k) Clearance for Corneal Pockets, Flaps

EyeGate Completes Enrollment, Receives Milestone Payment for Phase III Study of EGP-437 in Anterior Uveitis

SAV-IOL Seeks $20M in Financing for Active Intraocular Lens Concept with Real-Time Autofocus

AGTC Completes Enrollment for Phase I/II Study of Gene Therapy for X-linked Retinoschisis

Robert Greenberg, MD, PhD, Resigns from Second Sight

US FDA Requires RegeneRx to Conduct Third Phase III Trial for Dry Eye Candidate RGN-259

Stem Cell Implant Yields Positive Results in Phase I/II Study in Dry AMD

Drug Companies Petition Supreme Court to Hear Case Challenging Eye Drop Size

Appeals Court Rules in Favor of Alcon in Suit Brought by Elenza over EAIOLs

ThromboGenics’ THR-137 Demonstrates Safety, Tolerability in Phase I/II Study in DME

GenSight Biologics’ LHON Candidate Improves Eyesight, Fails to Outpace Sham in Phase III Trial

I-MED Pharma’s I-PEN Receives Regulatory Approval in Colombia, Argentina

Coming soon

2018 China Ophthalmic Market Report: An Analysis for 2017 to 2023